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Abstract 52 
Introduction Recessive mutations in GHRHR are associated with severe isolated GH 53 
deficiency (IGHD), with a final height in untreated patients of 130cm±10cm (-54 
7.2±1.6SDS; males) and 114±0.7cm (-8.3±0.1SDS; females). Objective We 55 
hypothesised that a consanguineous Pakistani family with IGHD in 3 siblings (2 56 
males, 1 female) would have mutations in GH1 or GHRHR. Results Two novel 57 
homozygous missense variants [c.11G>A (p.R4Q), c.236C>T (p.P79L)] at conserved 58 
residues were identified in all 3 siblings. Both were absent from control databases, 59 
aside from pR4Q appearing once in heterozygous form in the ExAc Browser. The 60 
brothers were diagnosed with GHD at 9.8 and 6.0 years (height SDS: -2.24 and -1.23 61 
respectively), with a peak GH of 2.9 μg/l with low IGF-1/IGFBP3. Their sister 62 
presented at 16 years with classic GHD (peak GH <0.1µg/l, IGF-1<3.3mmol/L) and 63 
attained an untreated near-adult height of 144 cm (-3.0 SDS); the tallest untreated 64 
patient with GHRHR mutations reported. An unrelated Pakistani female IGHD patient 65 
was also compound homozygous. All patients had a small anterior pituitary on MRI. 66 
Functional analysis revealed a 50% reduction in maximal cAMP response to 67 
stimulation with GHRH by the p.R4Q/p.P79L double mutant receptor, with a 100 fold 68 
increase in EC50. Conclusion We report the first co-existence of two novel 69 
compound homozygous GHRHR variants in 2 unrelated pedigrees associated with a 70 
partial loss of function. Surprisingly, the patients have a relatively mild IGHD 71 
phenotype. Analysis revealed that the pP79L mutation is associated with the 72 
compromise in function, with the residual partial activity explaining the mild 73 
phenotype.  74 
 75 
 76 
Introduction 77 
The gene encoding the growth hormone releasing hormone receptor (GHRHR) 78 
is 15.51kb in length and incorporates 13 exons on chromosome 7p14. It encodes a G-79 
protein coupled receptor (423aa) and is expressed on the somatotroph cells of the 80 
anterior pituitary (1). Its ligand growth hormone releasing hormone (GHRH), released 81 
from the hypothalamus, stimulates the synthesis and release of growth hormone (GH; 82 
encoded by GH1) upon binding in the presence of the pituitary-specific transcription 83 
factor POU1F1 (PIT1) (2,3). GH in turn binds to receptors on the liver and generates 84 
insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 85 
(IGFBP3), thereby promoting growth. 86 
Consistent with their role in growth regulation, mutations in GHRHR, GH1 87 
and SOX3 are implicated in the etiology of isolated growth hormone deficiency 88 
(IGHD) (4), and the pathway was recently implicated in the GHD phenotype observed 89 
in the autosomal dominant disorder pseudohypoparathyroidism type 1b (5). 90 
Autosomal recessive mutations occurring in the GHRHR gene have been implicated 91 
in severe IGHD Type 1B, also known as Sindh dwarfism (6,7). Reported aberrations 92 
in GHRHR have included missense, splice (8), nonsense (9,10), microdeletion and 93 
promoter mutations (11,12). Many have been shown to specifically affect cAMP 94 
production, for example GHRHR (p.K329E), which fails to show a cAMP response 95 
after treatment with GHRH (13). All mutations described to date have shown a 96 
complete loss of function.  97 
Severe IGHD Type 1B was initially described in pedigrees from the Indian 98 
subcontinent (14) and Brazil (15). Interestingly the phenotype is usually not that of 99 
classic IGHD in that affected patients have minimal facial hypoplasia and no 100 
microphallus, but do manifest anterior pituitary hypoplasia (APH) on their magnetic 101 
resonance imaging (MRI) (3). However, growth failure is severe with proportionate 102 
dwarfism and pubertal delay, and biochemically, the patients have low GH and IGF1 103 
concentrations with otherwise normal pituitary function. To date, reported height in 104 
untreated patients with a GHRHR mutation is on average 130 ± 10cm (-7.2 ± 1.6SDS) 105 
in males and 114 ± 0.7cm (-8.3 ± 0.1SDS) in females (16).  106 
Previous studies in our cohort of IGHD patients (n=224) revealed GHRHR 107 
mutations in 3.7% of cases (15 patients from 7 pedigrees). All were familial cases, 108 
predominantly from the South East Asian community, manifesting severe growth 109 
failure with the vast majority showing APH on their MRI (7). In this manuscript, we 110 
report the presence of two homozygous variants in GHRHR in consanguineous 111 
pedigrees with a relatively mild GHD phenotype, and present functional data that 112 
reveal the first partial loss of function mutation in GHRHR. Additionally, an 113 
independent patient with the identical variants was also identified, suggesting the 114 
presence of a founder effect. 115 
 116 
Materials and Methods 117 
 118 
Patients  119 
DNA was extracted from blood samples taken from two consanguineous 120 
pedigrees with IGHD. Ethical committee approval was obtained from the Institute of 121 
Child Health/Great Ormond Street Hospital for Children Joint Research Ethics 122 
Committee and informed written consent was obtained from patients and/or parents.  123 
 124 
Direct Sequencing Analysis 125 
Three siblings with IGHD from Pedigree 1 and a separate patient from 126 
Pedigree 2 were screened for GH1 and GHRHR mutations. The coding region of these 127 
genes consists of 5 exons in GH1 and 13 exons in GHRHR. These were amplified by 128 
PCR on an Eppendorf Thermocycler over 35 cycles with primers designed using the 129 
Primer3 program (available at http://frodo.wi.mit.edu/primer3) flanking each of the 130 
exons in the coding regions of the genes. PCR products were treated with MicroClean 131 
reagent (Web Scientific, cat # 2MCL-10) according to manufacturer’s instructions 132 
and then sequenced using BigDye v1.1 sequencing chemistry (Applied Biosystems) 133 
and analysed on a 3730X1 DNA Analyzer (Applied Biosystems/Hitachi, Japan, cat # 134 
625-0020). Details of the PCR conditions are available upon request including the 135 
primer sequences, product sizes and annealing temperatures. For any mutations 136 
identified, control databases were consulted as follows: Exome Variant Server 137 
(evs.gs.washington.edu/EVS/) (EVS), 1000 Genomes (www.1000genomes.org), an 138 
in-house panel of 200 ethnically matched controls, and the Exome Aggregation 139 
Consortium (ExAC Browser) (http://exac.broadinstitute.org/).  140 
Molecular modelling 141 
The RasMol prediction model database was used to build a 3D annotated 142 
model of the GHRHR wild type and mutant proteins respectively, to analyse and 143 
compare protein folding and structure.  144 
Functional analysis: 145 
An expression vector was obtained encoding full-length wild-type GHRHR 146 
cloned into pcDNA3.1 (Source Bioscience). Detected mutations p.R4Q, p.P79L and 147 
the double mutant p.R4Q/p.P79L were introduced into the sequence using the 148 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies UK LTD). 149 
Vectors were transfected into HEK293 cells (American Type Culture Collection) 150 
cultured in DMEM supplemented with 10% foetal bovine serum, 100U/ml penicillin, 151 
100μg/ml streptomycin and 1% non-essential amino acids at 37oC in a humidified 5% 152 
CO2 incubator. Approximately 1x10
6 cells were transfected with 1.2 µg Glosensor 153 
22F (Promega, Madison, WI, USA) and 1.2 µg GHRHR using Polyjet transfection 154 
reagent (SignaGen laboratories, Gaithersburg, MD, USA) according to the 155 
manufacturer’s instructions. Cells were plated in a white 96-well dish at a density of 156 
approximately 35,000 cells per well and the following day media replaced with 157 
Leibovitz’s L-15 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 158 
2mM luciferin (Promega). After equilibration at 25oC, the basal luciferase activity 159 
was measured on a Glomax luminometer (Promega) and cells were then stimulated 160 
with various concentrations of GHRH 1-44 (Bachem, Bubendorf, Switzerland) and 161 
the luciferase response monitored approximately every 3 minutes over a period of at 162 
least 60 minutes. Response to GHRH was calculated as the area under the curve for 163 
the time period of measurement after correction for background activity from 164 
unstimulated cells.  165 
 166 
Results  167 
Patient phenotypes: 168 
Patient IV.1 169 
 The proband was a male born at term (birth weight 3.6 kg) to a 170 
consanguineous Pakistani family (Figure 1A), and first presented at the age of 4 years 171 
with bilateral undescended testes, micropenis and a hypoplastic scrotum. There was 172 
no history of neonatal hypoglycemia or jaundice, he had no dysmorphic features, and 173 
at presentation his height was 100.7cm (-0.73 SDS) with a weight of 14.8kg (-1.09 174 
SDS). At the age of 4.2 years he had an acceptable testosterone response to a 3-day 175 
human chorionic gonadotrophin (hCG) stimulation test, rising from 0.4 to 4.8nmol/L 176 
and basal gonadotrophins in the pre-pubertal range (LH <0.7 U/L, FSH 1.0 U/L). 177 
Following hCG stimulation, testes were bilaterally palpable; however, later 178 
examination revealed impalpable testes and he received a further 6-week course of 179 
treatment with hCG at the age of 7 years with a partial response, and underwent 180 
bilateral orchidopexies at the age of 8.2 years. Between the ages of 4-7 years, he grew 181 
steadily with a growth velocity of 5.0-5.5 cm/year (-1.34 to -1.09 SDS), but by the age 182 
of 8.5 years, his height was 119.7cm (-1.91 SDS) and his growth velocity had slowed 183 
to 2.3 cm/year (-4.1 SDS). A glucagon stimulation test performed at the age of 9.8 184 
years (Ht 123.8cm, -2.24 SDS) showed a low peak GH (2.9µg/L) with otherwise 185 
normal pituitary function. He commenced treatment with recombinant human (rh) GH 186 
around the age of 10 years (mean dose 1mg/m2/day), progressed normally through 187 
puberty and attained a normal adult height of 170.4 cm (-0.65 SDS (Table 1); mid-188 
parental height of 169.2 cm, -0.8 SDS) (Figure 2A). Retesting at the end of growth 189 
demonstrated persisting GHD with a low IGF1 (6.9 nmol/l; range 29.4-117.4), an 190 
undetectable peak GH (<0.1 µg/L) (Table 2) to insulin tolerance test, and otherwise 191 
normal pituitary function. A pituitary MRI confirmed APH (Figure 2D) and he 192 
remained on adult rhGH replacement (0.6mg/day).  193 
 194 
Patient IV.2 195 
The younger male sibling (Figure 1A) of patient IV.1 first presented at the age 196 
of 1.5 years with bilateral undescended testes, micropenis and a hypoplastic scrotum. 197 
He was born at term with a birth weight of 3.64 kg and there was no history of 198 
neonatal problems. At presentation he had a height of 79.6 cm (-0.5 SDS) with a 199 
weight of 9.8 kg (-1.48 SDS) and no dysmorphic features. A 3-day and 3-week HCG 200 
stimulation test showed normal testosterone responses (11.1 nmol/l and 18.7 nmol/l 201 
respectively), with baseline gonadotrophins in the prepubertal range (LH <0.7U/L, 202 
FSH 1.7U/L); both testes were visualised in the inguinal canal. By the age of 2 years, 203 
he had a further 6-week hCG treatment course with good response in terms of 204 
testicular descent. However, at the age of 4 years, he had left testicular torsion with 205 
subsequent orchidectomy and right orchidopexy. By the age of 6 years his height was 206 
110.2 cm (-1.21 SDS) and his growth velocity had slowed to 3.6cm/year (-2.63 SDS) 207 
(Figure 2B). Glucagon stimulation test at that time confirmed GHD with a peak GH 208 
of 2.9µg/l and a low IGF1 (18 ng/ml; normal range (NR) 45-321 ng/ml) and IGFBP3 209 
(1.24 mg/l; range 1.86-4.39) (Table 2) with otherwise normal pituitary function and 210 
APH on MRI (Figure 2E). Treatment with rhGH was commenced at the age of 6.5 211 
years with an excellent response. By the age of 14.6 years, he had progressed into 212 
puberty with a height of 173.3cm (+1.02 SDS) and subsequently decided to stop 213 
rhGH. He has decided not to attend any further clinics. 214 
 215 
Patient IV.3   216 
The female sibling of patients IV.1 and IV.2 (Figure 1A) first presented at age 217 
16 years with short stature (height 144cm, -3.0 SDS). She had already attained 218 
menarche and had a clinical phenotype suggestive of untreated GHD (abdominal fat 219 
deposition, a high pitched voice and frontal bossing). She had an undetectable IGF1 220 
(<3.3 nmol/L), undetectable peak GH to insulin tolerance test (<0.1 µg/l) (Table 2), a 221 
low bone mineral density (-2.5 Z scores in lumbar spine) and APH on MRI (Figure 222 
2F). She was commenced on adult rhGH replacement (0.6mg/day) and reached a final 223 
height of 146.3cm (-2.7 SDS) (Table 1). She remains overweight, with acanthosis 224 
nigricans suggestive of insulin insensitivity (HOMA-IR of 3.1, peak insulin to oral 225 
glucose load of 143 mU/L, with a 2 hour blood glucose of 5.1 mmol/L).  226 
 227 
   228 
 229 
Patient II.1 230 
A female patient (unrelated to pedigree I) born to a consanguineous Pakistani 231 
pedigree (Figure 1B) with a birth weight of 3.32 kg, presented at age 6 years with 232 
short stature [height 104.3 cm (-1.8 SDS), weight 19.4 kg (-0.34 SDS)], poor growth 233 
with a growth velocity of 3.3 cm/year (-3 SDS), and APH on her MRI (Figure 2G). 234 
Biochemical testing revealed GH deficiency, with a peak GH to glucagon testing of 235 
1.1µg/l, an IGF1 of 17 ng/ml (NR 45-321 ng/ml) and an IGFBP3 of 1.52 mg/L (NR 236 
1.862-4.399 mg/L) (Table 2). At the age of 6 years she failed to respond to a GHRH 237 
test, and was subsequently commenced on rhGH treatment at a dose of 238 
0.65mg/m2/day (Figure 2C). She underwent spontaneous puberty and there were no 239 
concerns regarding her physical development. She has achieved a final height of 166 240 
cm (+0.66 SDS) (Table 1). Her father’s cousin has two daughters that are on GH 241 
treatment for short stature (DNA not available). 242 
 243 
Mutational analysis  244 
Following direct sequencing analysis of three siblings (pedigree I) and an 245 
unrelated female patient (pedigree II) with IGHD, two homozygous variants were 246 
identified in the GHRHR gene in all four patients. The first was a novel homozygous 247 
missense variant in exon 1 (c.11G>A) (Figure 1Ci) resulting in the substitution of 248 
arginine by glutamine (p.R4Q). The second was a novel homozygous missense 249 
variant in exon 3 (c.236C>T) (Figure 1Cii) resulting in the substitution of proline by 250 
leucine (p.P79L). Neither of these changes were identified on control databases 251 
including Exome Variant Server, 1000 genomes and the ExAc Browser, nor in 200 252 
ethnically-matched controls, with the exception of p.R4Q being present once on the 253 
ExAc browser in heterozygous form out of a total of 20,396 control alleles. Both 254 
p.R4Q and p.P79L have not been previously described and both are located within a 255 
highly conserved region between species (Figure 1D). All four patients were also 256 
screened for mutations in GH1 and were negative. 257 
 258 
Protein modelling 259 
Molecular modelling predicts that the GHRHR p.P79L variant will disrupt a 260 
disulphide bridge, thus destabilising the protein. In addition, the protein prediction 261 
model Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) predicted p.P79L to be 262 
functionally deleterious. Moreover, the crystal structure of a glucagon-like peptide-1 263 
in complex with the extracellular domain of its receptor (likely to have the same 264 
structure as the GHRHR extracellular domain) shows that residues close to p.P79 265 
interact with the ligand. Therefore, even if the mutant protein were to fold correctly 266 
without the disulphide bond in place (or with a weak disulphide bridge), the mutation 267 
is still predicted to disrupt the ligand-binding region.  268 
It was not possible to model the R4Q mutant as the model did not extend far 269 
enough into the N-terminus. This region is in the signal peptide and is outside the 270 
hydrophobic region shown to be required for function (17). Additionally, the arginine 271 
or glutamine at position 4 (p.R4Q) have identical scores for signal peptide prediction 272 
(SignalIP4.1). 273 
 274 
Luciferase assays 275 
Functional analysis was performed by monitoring cAMP responses of cells 276 
expressing wild-type and mutant GHRHR to varying concentrations of GHRH, and 277 
demonstrated that the double p.R4Q/p.P79L mutation had a significantly reduced 278 
maximal activity to 52.0+/-4.6% of wild-type GHRHR (p<0.001; Figure 3), with a 279 
reduction in affinity for the GHRH1-44 ligand (EC50 p.R4Q/p.P79L 113x10-11 +/- 280 
1.51x10-11 vs WT 1.12x10-11 +/- 0.21x10-11, p<0.001). Analysis of GHRHR protein 281 
with individual mutations demonstrated that p.P79L is responsible for both the 282 
reduction in activity (55.3+/-4.4% of wild-type, p<0.001) and the altered affinity 283 
(EC50 113x10-11 +/- 1.51x10-11, p<0.001 vs WT; non-significant difference vs 284 
p.R4Q/pP79L) (Figure 3). The single p.R4Q mutation had no significant effect on 285 
either maximal activity (p = 0.65) or EC50 (p = 0.9) compared with wild type 286 
GHRHR (Figure 3). Western analysis of cell extracts demonstrated no significant 287 
difference in the expression levels of the various forms of GHRHR (data not shown). 288 
 289 
Discussion 290 
We report two novel homozygous GHRHR variants in three siblings (Pedigree 291 
I; IV.1-IV.3), and in an unrelated patient (Pedigree 2; II.1), from consanguineous 292 
families from the South East Asian community, suggesting a possible founder effect. 293 
Pedigree I (incorporating patients IV.1-IV.3) is multiply consanguineous, with the 294 
parents of the probands being first cousins. Despite all patients having IGHD and 295 
APH on their MRI, the combined effect of these variants is variable in terms of height 296 
deficit, and the patients’ phenotypes are mild compared to previous reports, with 297 
presentation in mid-childhood. Indeed, the untreated female patient from pedigree I 298 
presented much later, after she had almost completed her growth, and reached a near-299 
adult height of 144cm (-3.0 SDS). Compared to the mean of ~114cm in the literature, 300 
this is the tallest untreated height reported for a patient with a GHRHR mutation to 301 
our knowledge. Subsequent treatment with an adult replacement dose of rhGH 302 
resulted in an improvement in her final height to 146.3 cm (-2.7 SDS). Surprisingly, 303 
the clinical presentation of the two brothers within the same pedigree with bilateral 304 
undescended testes, hypoplastic scrotum and micropenis was suggestive of 305 
hypogonadotrophic hypogonadism, although endocrine testing confirmed that the 306 
gonadal axis was intact and they progressed normally through puberty, with 307 
normalization of phallic size after commencement of rhGH treatment. The older 308 
brother and sister are now treated with adult GH replacement therapy.  309 
The asymptomatic mother of patients IV.1-IV.3 was a heterozygous carrier of 310 
both variants, and the father is also expected to be a carrier, although his DNA is 311 
unavailable. The presence of these two homozygous variants in the two ostensibly 312 
unrelated families raises the possibility that pedigrees I and II are distantly related or 313 
may originate from the same area in South-East Asia. 314 
Apart from a single report (18), patients with GHRHR mutations do not have 315 
neonatal hypoglycemia and in all reports to date they are reported to have normal 316 
genitalia. This is the first report of male patients with GHRHR mutations presenting 317 
with a micropenis and bilateral undescended testes. The mechanism underlying this 318 
presentation is unknown.  319 
A number of previously reported missense GHRHR mutations (p.H137L, 320 
p.L144H, p.A176V, p.A222E, p.F242C, p.K329E) have been shown to result in 321 
correct surface expression of the receptor but reduced ability to bind to GHRH, 322 
thereby impairing intracellular signalling and stimulation of GH secretion (19,13,20). 323 
However, a missense mutation (p.V10G) within the signal peptide has been shown to 324 
affect the correct processing of the receptor and results in incomplete cleavage of the 325 
signal peptide with failure of the mutant GHRHR receptor to translocate to the cell 326 
surface (17). The first variant, p.R4Q in exon 1, results in the substitution of a 327 
strongly basic arginine residue by a neutral glutamine residue. Despite our p.R4Q 328 
variant being located in the signal peptide, when arginine is substituted by tryptophan 329 
(p.R4W) at position 4 there is unaltered function, and this is consistent with our 330 
functional data whereby the p.R4Q variant appears to retain function (17). 331 
The second variant, p.P79L in exon 3 results in the substitution of a proline 332 
residue by leucine. Proline is known to be essential for protein folding (21); therefore 333 
its loss at this highly conserved position will likely affect protein conformation, which 334 
supports our protein prediction model for p.P79L. The functional assays performed 335 
further support this and conclude that the p.P79L mutation alters the binding affinity 336 
and activity of GHRHR, and is thus the likely cause of the GHD observed in patients 337 
IV.1-IV.3 and II.1. Therefore the 50% reduction in the maximal cAMP response to 338 
stimulation with GHRH observed by the p.R4Q/p.P79L double mutant receptor is 339 
most likely due to this pathogenic p.P79L mutation alone rather than the combination 340 
of both p.R4Q and p.P79L (Figure 3). Our studies do not rule out the possibility that 341 
the p.R4Q variant may be contributory in some way to the mild phenotype. 342 
 343 
Conclusion 344 
We report the presence of two novel homozygous variants in GHRHR in a 345 
pedigree, and an unrelated patient with IGHD, suggesting a possible founder effect of 346 
these variants in patients with IGHD originating from a certain area of South-East 347 
Asia. The initial phenotype of all patients appears to be relatively mild, despite the 348 
presence of the two variants in the same gene. We show here the importance of 349 
performing functional studies in this highly unusual scenario where two variants are 350 
present in compound homozygosity in affected individuals. All previously reported 351 
GHRHR mutations have been associated with complete loss of function. Our 352 
functional studies have shown that the novel p.P79L variant is pathogenic with what 353 
appears to be a partial loss of function, and is most likely the cause of the unusually 354 
mild form of IGHD in all four patients. Additionally, the female sibling in pedigree 1 355 
has the tallest recorded height for an untreated patient with a GHRHR mutation, and 356 
our data therefore suggest the possibility that rare patients with “idiopathic” short 357 
stature may manifest mild genetic forms of GHD and reach the target height range for 358 
the family without treatment.  359 
  360 
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 441 
Figures 442 
Figure 1. (A) Consanguineous Pakistani pedigree with IGHD. This family tree 443 
shows two male probands in Pedigree 1 and their affected sister (shaded black squares 444 
and a shaded circle respectively). The double lines represent consanguinity, with the 445 
parents of the affected patients being first cousins. The generations within the family 446 
are indicated by roman numerals. (B) Pedigree II with IGHD. This family consists 447 
of one affected female (shaded black circle) and her unaffected sister, born to first 448 
cousin parents. (C) Two GHRHR mutations associated with IGHD phenotypes. A 449 
novel homozygous missense mutation, c.11G>A causing a p.R4Q substitution, was 450 
identified in exon 1 (‘(i)’ - shown as ‘N’ and indicated by arrow) and a homozygous 451 
missense mutation; c.236C>T, causing a p.P79L substitution, was found in exon 3 452 
((ii)’ – shown by ‘N’ and indicated by arrow) in three siblings from pedigree I and in 453 
an unrelated female patient from pedigree II. (D) Highly conserved residues across 454 
multiple species. GHRHR protein sequences spanning both amino acids that are 455 
substituted in the patients. The p.R4 and p.P79 are represented in green and show high 456 
conservation between multiple species. Any spanning amino acid residues that differ 457 
from the reference human sequence are highlighted in red.   458 
 459 
Figure 2. (A-C) Growth charts of Patients IV.1, IV.2 and II.1. (A) Growth of 460 
patient IV.1 with GH treatment commencing at ten years of age. (B) Growth of 461 
patient IV.2 with GH treatment commencing at seven years of age (C) Growth of 462 
patient II.1 with GH treatment commencing at six years of age. (D-G) Pituitary MRI 463 
scan of patients IV.1, IV.2, IV.3 and II.1 respectively, presenting with a small anterior 464 
pituitary (indicated by the arrows).  465 
 466 
Figure 3. Functional analysis of mutant GHRHR proteins. Transfection of HEK293 467 
cells with wild-type or mutant GHRHR demonstrating the effects of mutations on 468 
GHRHR responses to stimulation with ligand. Transfected cells were stimulated with 469 
varying concentrations of GHRH and receptor activation monitored by cAMP 470 
accumulation in the cells (evaluated by cotransfection with the cAMP sensor Glosensor). 471 
Values shown are the mean+/- SE of three independent transfection reactions, with the 472 
data normalised to the maximal response of the wild-type receptor for each assay. ***: 473 
p<0.001 for both EC50 and maximum cAMP level, n.s.: not significant, one-way 474 
ANOVA, with Tukey post-hoc test. 475 
 476 
Table 1. Auxological parameters of affected patients. 477 
 478 
Table 2. Endocrine data from Pedigrees I and II. Endocrine values relative to age 479 
and MRI results for all patients: IV.1, IV.2, IV.3 and II.1.  480 
Table 1: Auxology on patients IV.1, IV.2, IV.3 and II.1 
Patient Sex Age 
(yrs) 
Ht 
SDS 
Wt 
SDS 
MRI Tx Age  
(yrs) 
Tx Adult Ht 
(cm) 
Adult Ht 
SDS 
IV.1 M 9.8 -2.24 -2.15 APH 10.3 rhGH 170.4 -0.65 
IV.2 M 6.2 -1.23 -0.48 APH 6.5 rhGH 173.3 1.02 
IV.3 F 16.0 -3.0 -1.06 APH Adult rhGH 146.3 -2.7 
II.1 F 6.0 -1.8 -0.34 APH 6.0 rhGH 166 0.66 
 
Table Click here to download Table Table 1.docx 
Table 2: Endocrine testing for patients IV.1, IV.2, IV.3 and II.1 
Patient Age 
yrs 
Peak GH 
(µg/L) 
IGF-1 
(ng/ml) 
IGFBP3 
(mg/L) 
FT4 
(pmol
/L) 
TSH 
(mU/L) 
PRL 
(mU/L) 
Cortisol 
peak 
(nmol/L) 
E2 
(pmol
/L) 
LH 
Basal 
(IU/L) 
LH 
Peak 
(IU/L) 
FSH 
Basal 
(IU/L) 
FSH 
Peak 
(IU/L) 
Testo 
(nmol/L) 
Chol 
(mmol/L) 
Chol
/HDL 
ratio 
US 
testes 
IV.1 4.2 - - - - - - - - <0.7 - 1.0 - D0 
0.4 
3d 
4.8 
- - - 
IV.1 9.8 2.9 18 (NR 
64-580) 
1.37 (NR 
2.265-
5.734) 
17.9 1.6 249 1067 - 0.7 3.4 0.3 1.7 - - - - 
IV.1 16.3 <0.1 6.9 
(nmol/L; 
NR 29.4-
117.4) 
- 21.1 1.29 221 688 - 4.2 11.4 3.1 4.2 32.4 - - - 
IV.2 1.6 - - - - - - - - <0.7 - 1.7 - D0 
<0.7 
3d 
11.1 
3wk 
18.7 
- - Inguinal  
canal 
IV.2 6.2 2.9 18 (NR 
45-321) 
1.24 (NR 
1.86-
4.39) 
21.1 2.1 221 669 - <0.7 10.2 5.3 18.9 - - - - 
IV.3 16.0 <0.1 <3.3 
(nmol/L; 
NR 30.8-
129.5) 
1.15 (NR 
3.2-8.7) 
15.8 4.63 196 733 123 3.4 - 5.2 - - 4.6 3.8 - 
II.1 6.5 1.1 
(Glucagon) 
1.2  
(GHRH) 
17 (NR 
45-321) 
1.52 
(mg/L; 
NR 1.86-
4.39) 
19.3 2.5 71 626 - - - - - - - - - 
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